Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Centogene N.V. (NQ: CNTG )

0.8201 -0.0799 (-8.88%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Centogene N.V.

CENTOGENE Reports Full Year 2022 Financial Results
From Centogene NV
Via GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in May
From Centogene NV
Via GlobeNewswire
CENTOGENE Receives Nasdaq Non-Compliance Notice
From Centogene NV
Via GlobeNewswire
CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline
From Centogene NV
Via GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in April
From Centogene NV
Via GlobeNewswire
CENTOGENE Launches NEW CentoGenome®, World’s Most Comprehensive Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases
From Centogene NV
Via GlobeNewswire
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
From Centogene NV
Via GlobeNewswire
CENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager - Pharma
From Centogene NV
Via GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in March
From Centogene NV
Via GlobeNewswire
In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)
From Centogene NV
Via GlobeNewswire
CENTOGENE Regains Compliance With Nasdaq Listing Requirements
From Centogene NV
Via GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day
From Centogene NV
Via GlobeNewswire
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics
From Twist Bioscience Corporation
Via Business Wire
CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics
Working together to deliver data-driven, informative genotyping answers to accelerate and de-risk drug discovery, development, and commercialization for Parkinson’s disease (PD) 
From Centogene NV
Via GlobeNewswire
CENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco
From Centogene NV
Via GlobeNewswire
CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
From Centogene NV
Via GlobeNewswire
CENTOGENE Receives Nasdaq Non-Compliance Notice
From Centogene NV
Via GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in December
From Centogene NV
Via GlobeNewswire
CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan
Adding significant financial expertise with an impressive track record in value creation 
From Centogene NV
Via GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in November
From Centogene NV
Via GlobeNewswire
CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network
From Centogene NV
Via GlobeNewswire
CENTOGENE to Participate in Upcoming Partnering Conferences in October
From Centogene NV
Via GlobeNewswire
CENTOGENE Reaches 12,500 Patient Milestone in World’s Largest Observational Study on Parkinson’s Disease Genetics
From Centogene NV
Via GlobeNewswire
Dammam Valley and Arcensus GmbH to establish Saudi-German Genomic Center in Riyadh
Via ACN Newswire
Dammam Valley/KSA to acquire the majority of Arcensus GmbH/Germany to accelerate the global implementation of Whole Genome Sequencing in genetic diagnostics and delivery of breakthrough technologies in genomic bioinformatics
Via ACN Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.